Abbott, BMS Suffer Blows On Antiretrovirals Kaletra and Reyataz As Indian Patent Office Rejects Patent Claims
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Deputy Controller of Patents and Designs from the Mumbai branch of the Indian Patent Office rejected Dec. 30 Abbott's patent request for its popular second-generation antiretroviral Kaletra (lopinavir/ritonavir). Abbott had applied for a patent of a heat stable formulation of Kaletra nearly three years ago
You may also be interested in...
Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 2 of 2)
Gilles Picard discusses how to reach patients across a mix of developed and frontier markets in his role as VP of Asia, Australia, Africa and the Middle East for AbbVie, the innovative biopharma company split from parent Abbott Laboratories at the start of the year.
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma